

MARKET ANNOUNCEMENT

Uscom Completes Thor Acquisition

Sydney, Australia: Tuesday, 1st September 2015: Uscom (ASX code: UCM) (the **Company** or **Uscom**), is pleased to announce it has completed its acquisition of 100% of Thor Laboratories following successful diligence and capital raising. Thor is a revenue stage, medical device manufacturer specialising in high fidelity digital Doppler technology for measurement of respiratory function. Thor has partnered with Cohero Health in New York for the development and marketing of world leading personal asthma monitoring products.

Thor Acquisition Summary:

- Cash flow positive medical technology company with high quality digital Doppler respirometry devices.
- Internationally accredited manufacturing, R&D and engineering facilities.
- Established distribution network, primarily in Europe.
- Multiple CE/TGA/FDA approved products, each with re-imbursement.
- Partnership with Cohero (New York) for marketing of Thor developed home care, cloud based, asthma and COPD monitoring technologies.
- George Ferenczi and team to join Uscom providing international footprint.
- Complementary technologies with synergies of science, technology and operations.

The acquisition will expand the Uscom footprint internationally and include the addition of of approximately 16 engineers, and 10 administrative staff based in Hungary. George Ferenczi, the Thor founder and a world leader in respiratory devices, also joins the Uscom team and will lead new product development. The Thor manufacturing facilities in Budapest will provide expanded manufacturing capacity to meet the increased demand for USCOM 1A, and the US marketing of Uscom BP+, and the expansion of Thor products into the US following FDA approval in June 2015.

Uscom CEO, Associate Professor Rob Phillips said, "This acquisition is another great step for shareholders adding value at many levels: revenue, scale, manufacturing, distribution, products and international market partnerships. The devices are Doppler ultrasound based, like USCOM 1A, and relate to the cardiopulmonary clinical market. Thor will provide a high quality, approved and manufacturing base close to international markets. Hungary is a European manufacturing secret, providing highly cost-effective manufacturing for the medical device companies of Germany and Switzerland. The Thor products are innovative with an expanding market recognition and will be managed under under Stephen Wilson's guidance in the US now they have FDA approval. We are looking forward to working closely on development of both the current Uscom products and the Thor products with our new expanded team. We have grown our staff from 12 to 38 overnight with all the development, distribution and management efficiencies that brings, at a time when our rapid growth requires it most. This is a very fortuitous partnership at exactly the right time."

Stephen Wilson, Uscom's US VP of Business Development said, "George and I displayed some of the Thor devices at the FIME medical device conference in Florida last month and there was considerable excitement. I think these products have a great future in the US asthma and COPD market, and particularly for home care and cloud based monitoring, and I am looking forward to developing the distribution partnerships to make that happen."

The new suite of Thor spirometric devices will slipstream Uscom's flagship USCOM 1A and Uscom BP+ products and expand Uscom technology into practice leading positions in cardiac, vascular and pulmonary applications.



MARKET ANNOUNCEMENT

About Uscom

Uscom Limited (UCM) is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular and pulmonary devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the Uscom BP+. The Thor suite of products address the growing markets of asthma and COPD. All devices are clinically validated with FDA, CE and TGA regulatory registrations, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects circulatory abnormalities and guides treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, heart failure, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread sub systolic Blood Pressure monitoring technologies focused on arm measurements. Central Blood Pressure is emerging as the new standard of care in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and arterial pulse pressure waveforms, measures otherwise only available by cardiac catheterisation. The Uscom BP+ is simple to use and measures from a familiar upper arm cuff, and requires no complex training, and has applications in cardiology, intensive care, general practice and home care.

The Thor suite of products are adapted for highly accurate measurement of lung function using advanced spirometers using digital Doppler ultrasound technology. This clinical information is used to detect and monitor asthma and COPD, and monitor the effectiveness of clinician and home administered medications. This digital technology is ideally suited to cloud based recording and telemetric assessment, allowing remote clinician management and improved patient compliance using self administered therapy.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Assoc. Professor Rob Phillips Executive Chairman rob@uscom.com.au Catherine Officer Company Secretary secretary@uscom.com.au